Skip to content

Ganglioside GM2 (Serum) by Line Blot Assay

Published: August 9, 2026Updated: August 16, 2026

This test measures the presence of GM2 ganglioside in your blood, a lipid molecule that can help identify certain inherited metabolic disorders, including Tay-Sachs disease.

Quick summary

["This screening helps detect genetic conditions affecting lipid metabolism."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
89524-3
Short code
GM2 Gangl IgM Ser Ql Line blot
Synonyms
GM2 Gangl IgM Ser Ql Line blot
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
line-blot
CPT
82784
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why This Test Is Done

Your healthcare provider may order this test if you have symptoms like developmental delays, muscle weakness, or neurological issues that could be linked to GM2 ganglioside-related disorders. It’s also used in research or genetic counseling settings for families with a history of these conditions.

What to Expect Before the Test

No special preparation is needed. You’ll have a small needle inserted into your arm to draw blood. It usually takes about 15 minutes. If you’re nervous, let your provider know—we can help make it more comfortable.

What the Results Mean

Results are qualitative (yes/no presence) rather than quantitative. Elevated levels of GM2 ganglioside may suggest Tay-Sachs disease or other lysosomal storage disorders, prompting further genetic testing or specialist evaluation.

Common Symptoms Linked to This Test

Conditions like Tay-Sachs disease often present in infancy with symptoms such as loss of developmental milestones, seizures, or difficulty moving. Early detection through screening can improve long-term outcomes.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Clinical Significance: This test is primarily used as a screening tool for inherited metabolic disorders. GM2 ganglioside accumulation is characteristic of lysosomal storage diseases, including Tay-Sachs disease, which affects nerve cells and can lead to severe neurological impairment. Results guide next steps, such as genetic counseling or specialized care.

Short name

GM2 Ganglioside Screening

Frequently asked questions

What does a positive result mean?
A positive result indicates the presence of GM2 ganglioside in your blood, which may suggest Tay-Sachs disease or another lysosomal storage disorder. This finding will be reviewed by a healthcare provider to determine next steps, such as genetic testing or further evaluation.
How often should I get this test?
This test is typically ordered as part of a specific clinical evaluation or research study. Your healthcare provider will advise on frequency based on your symptoms, family history, or other factors.
Can lifestyle changes affect this test result?
No, this test measures a genetic trait and is not influenced by diet, exercise, or other lifestyle factors. Results reflect your inherent metabolic profile.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy